white → brown1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
WARNINGMIXING OR WITHDRAWAL CAN BE DANGEROUS
Ordinary doses in combination with other depressants can fatally stop breathing. After prolonged dependency, stopping suddenly can also cause seizures or delirium; seek medical help.
Pyrazolam
8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
SH-I-04
Pyrazolam is a research chemical depressant of the triazolobenzodiazepine class. Originally developed at Hoffmann-La Roche in the 1970s, it emerged on the research chemical market around 2012citation needed. Pyrazolam is distinguished from other benzodiazepines by its predominantly anxiolytic profile, producing comparatively less sedation and euphoria at common doses. It is structurally related to alprazolam and bromazepam and is notably reported to pass through the body unmetabolized.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~0.5 mg
Light0.5-0.75 mg
Moderate0.75-1.5 mg
Strong1.5-3 mg
Heavy3+ mg
Duration
Onset10-15 minutes
After Effects1-12 hours
Total5-8 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
The physical effects of pyrazolam can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The general head space of pyrazolam is described by many as one of mild sedation and proportionlly intense anxiety suppression. It contains a large number of typical depressant cognitive effects.
Pharmacology
Pharmacodynamics
Pyrazolam acts as a positive allosteric modulator at the GABAA receptor via the benzodiazepine binding site, enhancing the inhibitory signaling of GABA.citation needed It is most selective for the α2 and α3 subtypes of the GABAA receptor, which is consistent with its predominantly anxiolytic profile. The anticonvulsant properties observed with benzodiazepines as a class may be partly attributable to interaction with voltage-dependent sodium channels rather than the benzodiazepine site itself.1
Pharmacokinetics
Pyrazolam does not appear to undergo metabolism and is instead excreted unchanged in the urine. As a result, it does not interact with liver enzymes, which may make it comparatively safer for individuals with reduced hepatic function.citation needed
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Sedative-hypnotic tolerance can appear after only a few days of uninterrupted use.
Cross Tolerance
Benzodiazepines
Baseline Reset
Tolerance typically returns to baseline within 7-14 days after cessation, though this period may be significantly longer for individuals with extended or intensive use histories.
Harm Potential
Addiction & Dependence
Psychological
HighPyrazolam is described as extremely psychologically addictive, with compulsive redosing commonly reported as a cognitive effect. However, its comparatively limited sedative and euphoric effects relative to other benzodiazepines may somewhat reduce recreational appeal and abuse potential.
Physical
Extremely HighPhysical dependence develops with regular use. Withdrawal following a few weeks or longer of steady dosing can be potentially life-threatening, with symptoms including hypertension and seizurescitation needed; abrupt discontinuation after extended use may result in death. Gradual tapering over weeks is strongly recommended.2
Seizure Risk
While benzodiazepines have anticonvulsant properties during use2, abrupt discontinuation after regular use can cause potentially fatal seizures.citation needed Paradoxical seizure reactions during use are rare in the general population, with an incidence rate below 1%, occurring more frequently in epileptics and high-dosage regimes.
History & Culture
Pyrazolam was originally developed during the 1970s by a research team led by Leo Sternbach at Hoffman-La Rochecitation needed, the pharmaceutical company responsible for discovering many clinically significant benzodiazepines. Despite its initial synthesis during this prolific period of…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
By Country
Illegal3
SwedenIllegalFörordning (1992:1554) om kontroll av narkotika, current consolidated text29
The current Swedish statutory annex expressly names pyrazolam, establishing its narcotics classification. The annex specifies neither a more specific Swedish schedule number nor penalties.
TurkeyIllegalCouncil of Ministers Decision No. 2016/9712, adopted 27 December 2016 and published 12 January 2017 in Official Gazette No. 29946, annexing Pyrazolam to the substances subject to Article 19 of Law No. 2313 on the Control of Narcotic Drugs; conduct-specific Turkish Penal Code No. 5237 (TCK), Articles 188, 190 and 191.313233343536373839
Pyrazolam is listed under Turkey's Decision No. 2016/9712. The 2026 UNODC national legal-response record names pyrazolam among Turkey's controlled benzodiazepines and links the Official Gazette decision. Law No. 2313 is Turkey's NPS-control vehicle, including generic classification and EWS referrals. The official Narkotik EWS page is dated 8 August 2024, and the official report is dated 2025. TCK Articles 188, 190 and 191 are conduct-specific, so imprisonment and fine ranges vary by possession or import scenario rather than constituting a single penalty. Decision No. 2016/9712 names Pyrazolam but prints the divergent descriptor, 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, whereas the UNODC identity record gives 6-(pyridin-2-yl); Pyrazolam is directly listed by name and the discrepancy remains. UNODC gives the IUPAC name 8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine, places it in the benzodiazepine substance group and sedative/hypnotic effect group, and records molecular formula C16H12BrN5, molecular weight 354.204 g/mol, InChIKey BGRWSFIQQPVEML-UHFFFAOYSA-N, with no CAS number displayed. Article 188(4)(a)'s half-increase concerns listed synthetic-cannabinoid, cathinone, opioid or amphetamine derivatives; Pyrazolam has not been classified as one of those derivatives.
Controlled / restricted3
GermanyNpSG controlledControlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019.6 Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty.
SwitzerlandRestrictedBetäubungsmittelverzeichnisverordnung (BetmVV-EDI), status 13 March 202630
The current Fedlex schedule lists pyrazolam in controlled Verzeichnis-e. The schedule does not establish broad possession and distribution penalties.
United KingdomClass CControlled as a Class C substance under the Misuse of Drugs Act 1971 since May 31, 2017.40 Prior to this, a Temporary Class Drug Order (TCDO) issued in December 2016 had already prohibited personal possession, not just import and supply. It is illegal to possess, produce, or supply.
Prescription1
RussiaPrescription onlyGovernment Resolution No. 681 of 30 June 1998, current consolidated text amended 11 June 2025 (List III psychotropic substances); Government Resolution No. 827 of 12 July 2017 (adding pyrazolam to List III and to the quantity table); Federal Law No. 3-FZ of 8 January 1998, Articles 1, 14(2),(4) and 25(1)-(2); Government Resolution No. 1002 of 1 October 2012, current quantity table amended 11 June 2025; Criminal Code No. 63-FZ of 13 June 1996, Articles 228 and 228.1; Code of Administrative Offences No. 195-FZ of 30 December 2001, Article 6.8.78910111213141516171819202122232425262728
Pyrazolam was added to Russian List III in 2017. Russian List III is a restricted psychotropic category, not a generic 'illegal drug' or unrestricted status: Article 14(2) permits medical and specified statutory circulation, Article 25 requires prescription dispensing for List III psychotropic medicines, and Article 14(4) separately prohibits turnover of analogues. The current List III quantity thresholds for pyrazolam are more than 1 g (significant), more than 5 g (large) and more than 1000 g (especially large), not permitted possession limits. Article 228 addresses no-sale acquisition/storage/transport/manufacture/processing, Article 228.1 addresses production/sale/forwarding, and Article 6.8 provides the administrative no-sale baseline where applicable; charging remains dependent on amount, intent, substance identity, facts and applicable law at the time.
References
Source Pages
Citations
- M. J. McLean, & R. L. Macdonald. (1988). Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. Journal of Pharmacology and Experimental Therapeutics, 244(2), 789–795. https://pubmed.ncbi.nlm.nih.gov/2450203/123
- Controlled Drugs and Substances Act, Schedule IV (current to 21 June 2026). laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html1
- Status determination of benzodiazepines. canada.ca (n.d.). https://www.canada.ca/en/health-canada/corporate/mandate/regulatory-role/what-health-canada-regulates-1/controlled-substances-precursors/overview-substance-control-status-determination-process/benzodiazepines.html1
- New psychoactive substances in Canada - 2022. canada.ca (n.d.). https://www.canada.ca/en/health-canada/services/publications/healthy-living/new-psychoactive-substances-canada-2022.html1
- Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes, BGBl. I 2019 S. 1083. (n.d.). https://www.buzer.de/gesetz/13500/index.htm1
- PubChem PUG REST pyrazolam identity record. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/pyrazolam/property/IUPACName,CanonicalSMILES,InChIKey,MolecularFormula/JSON1
- Roszdravnadzor official card for Government Resolution No. 681. roszdravnadzor.gov.ru (n.d.). https://www.roszdravnadzor.gov.ru/drugs/licensingdrugs/documents/1671
- Current consolidated Government Resolution No. 681 schedule. roszdravnadzor.gov.ru (n.d.). https://www.roszdravnadzor.gov.ru/i/upload/images/2026/3/30/1774879151.29078-1-3386659.pdf1
- Official legal-information consolidation of Government Resolution No. 681. ips.pravo.gov.ru (n.d.). https://ips.pravo.gov.ru/api/ips/legislation/document?baseid=None&hash=4f3e2b09ec67c44a6cf6a43dadfa2bb8f18b308deee875a951cc59a78f8eb6501
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
31 August 2026
Lyrea · Updated the article
20 August 2026
Lyrea · Added a citation in Pharmacology › Pharmacokinetics
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Pyrazolam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.